Cardiovascular Solutions for Medical Device Companies
Scale new therapies in the structural heart field faster and more effectively with AI-driven 3D insights for predictive, intuitive planning. 3D technology can support you from research and development to clinical trials and after-market clearance. Realize cost benefits with robust and scalable processes to efficiently reach more patients.
Benefits along the product lifecycle
Research and Development
- Design devices that fit complex anatomy by creating accurate 3D models to visualize and measure
- Build evidence to obtain regulatory clearance by using realistic in vitro and in silico test setups
- Quantify the target population on a substantial number of virtual patients to maximize population coverage and receive relevant design input.
- Avoid surprises in the cath lab and optimally prepare physicians with consistent patient planning
- Use medically cleared tools to obtain favorable clinical outcomes while ensuring data integrity
- Automate your 3D planning workflow to efficiently scale up the increasing number of cases from feasibility to pivotal trials
- Select the most suitable patients using accurate 3D measurements
- Prepare physicians to adopt your device with intuitive, detailed 3D insights on the implant-anatomy interaction
- Automate your 3D planning workflow to efficiently scale up the increasing patient numbers while reducing time and inter-user variability
- Collect evidence and prioritize outcomes for patients with reliable tools for 3D post-op analysis and post-market trials
- Facilitate effective communication and case management with a centralized and customizable collaboration platform
patients helped yearly
years in structural heart
scans analyzed with medical software
We are glad to know that Materialise as a company listens to feedback and continuously improves software and our tools. I know if you have a good team and good clinical input together, you always get a good outcome.
Discover how medical device companies benefit from our solutions in the structural heart and cardiovascular field.